The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation

46Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rhabdomyosarcoma (RMS) is a pediatric tumor that arises from muscle precursor cells. RMS cells express several markers of early myogenic diferentiation, but they fail to complete both diferentiation program and cell cycle arrest, resulting in uncontrolled proliferation and incomplete myogenesis. previous studies showed that eZH2, which is involved in both diferentiation and cancer progression, is overexpressed in RMS, but a functional binding between its expression and its functional role in tumor formation or progression has not yet been demonstrated. We hypothesized that eZH2 is a key regulator of muscular diferentiation program in RMS cells. In this study, we demonstrated that eZH2 directly binds muscle specifc genes in RD cells. Silencing of eZH2 promotes the recruitment of a multiprotein complex at muscle-specifc promoters, their transcriptional activation and protein expression. Moreover, we demonstrated that eZH2 is directly involved in transcriptional repression of MyoD, the main factor promoting myogenesis. eZH2 ablation induces MyoD activation the recovery of its binding on muscle-specifc genes. © 2012 Landes Bioscience.

Cite

CITATION STYLE

APA

Marchesi, I., Fiorentino, F. P., Rizzolio, F., Giordano, A., & Bagella, L. (2012). The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle, 11(20), 3828–3836. https://doi.org/10.4161/cc.22025

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free